Search results
Aimin Xu is currently a Chair Professor jointly appointed by the Department of Medicine and the Department of Pharmacology & Pharmacy, and also the director for State Key Laboratory of Pharmaceutical Biotechnology (www.sklpb.hku.hk) at the University of Hong Kong.
Aimin Xu. Department of Medicine, Department of Pharmacology and Pharmacy, the University of Hong Kong. Verified email at hku.hk. Obesity diabetes biomarker discovery adipocyte biology adipokines. Articles Cited by Public access. Title. ... AWK Tso, A Xu, PC Sham, NMS Wat, Y Wang, CHY Fong, BMY Cheung, ... Diabetes care 30 (10), 2667-2672, 2007 ...
The HKU Scholars Hub is the current research information system of The University of Hong Kong. As a key vehicle of HKU's Knowledge Exchange Initiative, The Hub aims to enhance the visibility of HKU authors and their research, and to foster opportunities for collaboration.
Aimin XU | Cited by 36,452 | of The University of Hong Kong, Hong Kong (HKU) | Read 711 publications | Contact Aimin XU
Proceeding/Conference: 30th European Congress on Obesity - ECO 2023 (17/05/2023-20/05/2023, Dublin)
2. Dong Z, Su L, Esmaili S, Iseli TJ, Ramezani-Moghadam M, Hu L, Xu A, George J, Wang J. Adiponectin attenuates liver fibrosis by inducing nitric oxide production of hepatic stellate cells. J Mol Med. 2015 Jul 9. [Epub ahead of print] (IF=4.739) 3. So WY, Cheng Q, Xu A, Lam KSL, Leung PS. Loss of fibroblast growth factor
Professor Xu focuses on basic, clinical and translational research on obesity, diabetes and cardiovascular complications. He discovered the bioactive form of the anti-diabetic hormone adiponectin, and uncovered the potential of adiponectin in protection against obesity-related fatty liver and vascular diseases.
